Want to commission a custom market research to suit your needs? We are here to help. Let us know.
Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players
GlobalData has released its pharma report, “Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Hemophilia A and B Market. The report identifies and analyses the key companies shaping and driving the global Hemophilia A and B market. The report provides insight into the competitive Hemophilia A and B landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
- Investigation of current and future market competition for Hemophilia A and B
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Hemophilia A and B sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving Hemophilia A and B market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Hemophilia A and B market landscape? Identify, understand and capitalize
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.2 Drivers and Barriers - Global Market
4 Current and Future Players
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.4 CSL Behring
4.3.5 Novo Nordisk
5.4 Forecasting Methodology
5.4.1 Diagnosed Hemophilia Patients
5.4.2 Percent Drug-Treated Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Pricing of Pipeline Agents
5.5 Primary Research - KOLs Interviewed for this Report
5.6 Primary Research - Prescriber Survey
5.7 Real-World Data
5.8 About the Authors
5.8.2 Therapy Area Director
5.8.4 Global Head of Healthcare
5.9 About GlobalData
1.1 List of Tables
Table 1: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the 7MM+A, 2014-2024
Table 2: Global Hemophilia A and B Market - Drivers and Barriers, 2014-2024
Table 3: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2014-2024
Table 4: Baxalta’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 5: Baxalta SWOT Analysis, 2015
Table 6: Bayer’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 7: Bayer SWOT Analysis, 2015
Table 8: Biogen’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 9: Biogen SWOT Analysis, 2015
Table 10: CSL Behring’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 11: CSL Behring SWOT Analysis, 2015
Table 12: Novo Nordisk’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 13: Novo Nordisk SWOT Analysis, 2015
Table 14: Pfizer’s Hemophilia Recombinant Portfolio Assessment, 2015
Table 15: Pfizer SWOT Analysis, 2015
Table 16: Key Launch Dates
Table 17: Physicians Surveyed
1.2 List of Figures
Figure 1: Global Sales for Hemophilia A and B Recombinant Therapies by Region, 2014-2024
Figure 2: Company Portfolio Analysis in Hemophilia A and B, 2014-2024
Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?
If yes, then please use the form given below and we will get in touch with you immediately.
Kindly use your official email address and contact number to ensure speedy response.